SCHEMBL6487987

SCHEMBL6487987

NC(=O)c1cccc2cc3cc4ccccc4c-3[nH]c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
PDPK1 O15530 1/20 0.46
MAPT P10636 1/20 0.44
PIM1 P11309 1/20 0.44
GFER P55789 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PLK4 O00444 1/20 0.44
CHEK1 O14757 1/20 0.44
AURKA O14965 1/20 0.44
DAPK3 O43293 1/20 0.44
MAP4K4 O95819 1/20 0.44
CSF1R P07333 1/20 0.44
RET P07949 1/20 0.44
FGFR1 P11362 1/20 0.44
PDGFRA P16234 1/20 0.44
LTK P29376 1/20 0.44
KDR P35968 1/20 0.44
MAP2K2 P36507 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8633600 0.87 KDM4E (0.60) KDM4EALDH1A1MAPTPIM1GFER
SCHEMBL6029052 0.75 DHODH (0.49) KDM4EALDH1A1GAAPDPK1PLK4
SCHEMBL6028084 0.75 DHODH (0.59) KDM4EALDH1A1GAAPDPK1PLK4
SCHEMBL6029606 0.73 DHODH (0.78) KDM4EALDH1A1GAAPDPK1PLK4
SCHEMBL31423274 0.73 PDPK1 (0.53) KDM4EALDH1A1GAAPDPK1PLK4
SCHEMBL19857562 0.73 PDPK1 (0.53) KDM4EALDH1A1GAAPDPK1PLK4
SCHEMBL9474474 0.73 DYRK1A (0.49) CHEK1FLT3CASP7
SCHEMBL29696398 0.73 PDPK1 (0.53) KDM4EALDH1A1GAAPDPK1PLK4
SCHEMBL8821216 0.72 BCAT2 (0.50) KDM4EALDH1A1GAAPDPK1MAPT
SCHEMBL6028357 0.72 DHODH (0.59) PDPK1TDP1PLK4CHEK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187172-A1 Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia PFIZER INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187172-A1 Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia TOP2A, TOP2B, TOP1 KDM4E 3266/4885ALDH1A1 1202/4885GAA 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.